武汉云克隆科技股份有限公司

Abstract: Transplantation of pancreatic islets of Langerhans (islets) is a promising method to treat insulin-dependent diabetes mellitus. Control of complement activation is necessary to improve graft survival inalloislet and xenoislet transplantation. In this study, human soluble complement receptor 1 (sCR1) wasimmobilized on the islet cell surface through poly(ethylene glycol)-conjugated phospholipid (PEG-lipid)without loss of islet cell viability or insulin secretion ability. sCR1 on islets effectively inhibits complement activation and protects islets against attack by xenoreactive antibodies and complement. This method will be an efficient means to control early islet loss in clinical islet transplantation and realizexenoislet transplantation in the future.

摘要：胰岛移植胰岛（胰岛）是治疗胰岛素依赖性糖尿病的有希望的方法。 补充激活的控制对于改善肝和小叶移植中的移植物存活是必需的。 在本研究中，人类可溶性补体受体1（sCR1）通过聚（乙二醇）偶联的磷脂（PEG-脂质）在胰岛细胞表面固定化，而不丧失胰岛细胞活力或胰岛素分泌能力。 sCR1对胰岛有效抑制补体活化并保护胰岛免受异种反应性抗体和补体的攻击。 该方法将成为控制临床胰岛移植早期胰岛损失，实现未来小叶移植的有效手段。

使用试剂原文信息：Sera were collected to observe insulin leakage from destroyed islets. Insulin concentrations in the sera were determined by ELISA. To see activation of the complement system, C3a concentration in the sera were determined by ELISA (USCN Life Science Inc., Wuhan, China).